EP Patent

EP3179992B1 — Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Assigned to Acerta Pharma BV · Expires 2022-05-11 · 4y expired

What this patent protects

Patent listed against acalabrutinib-maleate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3179992B1
Jurisdiction
EP
Classification
—
Expires
2022-05-11
Drug substance claim
No
Drug product claim
No
Assignee
Acerta Pharma BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.